The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and ...

Shares of Novo Nordisk slipped in Monday morning trading after the company announced results of its latest weight-loss drug trial. Novo's results from its Redefine 2 late-stage trial of ...

Novo Nordisk announced that its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes lose 15.7% of their weight in a recent trial. That figure ...

Novo Nordisk (NVO) is not concerned by the ongoing ... with a $2.5 billion API production site, and is building out the next step in the supply chain — a $4.1 billion fill-and-finish factory ...

Novo Nordisk said Wednesday it will sell Wegovy ... don’t take into account the expensive work of research and development, or building the manufacturing facilities necessary to churn out ...

Shares of Novo Nordisk fell on Monday, after the Danish pharmaceutical giant said its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes drop ...

This collaboration unites Novo Nordisk’s deep therapeutic knowledge and drug development experience with Gensaic’s novel protein design technology with the aim to discover tissue targeting ...

Novo Nordisk is rolling out a new national marketing campaign for its GLP-1 juggernaut, teaming up with celebrities and other patients to show what life looks like in their “Ozempic Eras.” ...

Novo Nordisk's (NYSE: NVO ... The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month ...